Canopy Growth: Canaccord Estimates $101.1 Million In Top Line Revenue For Q1 2021

Canopy Growth (TSX: WEED) (NYSE: CGC) will report their first fiscal quarter of 2021 on August 10th before market open with the call following at 10:00 am. With a C$2.2 billion annualized run-rate that is the Canadian market, Canaccord analyst Matt Bottomley says that COVID-19 is likely to weigh on the quarter, as sales from licensed producers to distributors have most likely been impacted more heavily than what retail data suggests.

Canaccord’s Matt Bottomley estimates are forecasting that Canopy’s recreational cannabis revenue come in at C$40.8 million, which is around C$9 million lower than the fourth fiscal quarter of C$49.7 million or an 18% decrease quarter over quarter. Meanwhile Gross Domestic Medical and Gross International Revenue are currently estimated to bet C$14.6 million and C$20.9 million, respectively, which will be flat quarter over quarter. Finally, Total Revenue totaling C$101.1 million is estimated for the quarter, C$14 million lower than last quarter’s figure or a 12% decrease quarter over quarter.

Bottomley states that even though Cannabis 2.0 sales are expected to be over 10% of total says during this quarter, due to “less favourable provincial purchasing patterns” and the closing of many of Canopy’s owned retail stores is the reasoning behind why they are forecasting C$40.8 million in revenue or a decrease of 18% quarter over quarter. Alongside forecasting flat international and Canadian medical sales quarter over quarter, Bottomley is also forecasting a 16.5% decline in Canopy’s “other” revenue streams. Management has cited that the segment has rebounded modestly from the 30% declines it saw at the start of the quarter. For these reasons, Canaccord forecasts net revenue to come in at C$94.7 million, or down 12% from last quarter.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

The last thing to note is that Canaccord is forecasting Canopy’s cash position to come in around C$2 billion, as the exercise of C$245 million in warrants by Constellation Brands offsets the estimated C$225 million in operating and capital expenses for the quarter.

Currently, Canaccord has a hold rating and a C$21 price target on Canopy Growth.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Canada Is Finally Fast-Tracking New Mines | John Passalacqua – First Phosphate

Gold & Silver Just Added $2 Billion to This Project | Aya Gold – Bourmadine PEA

Recommended

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Japan Gold Lands $50 Million in Committed Capital Through Solidcore Alliance

Related News

BMO Reiterates Ratings On Eldorado Gold Despite Poor Quarterly Performance

Eldorado Gold (TSX: ELD) is down 8% since it reported its first-quarter financial results on...

Tuesday, May 3, 2022, 02:22:00 PM

BMO Reiterates $72 Price Target On Kirkland Lake Gold

Last week, Kirkland Lake Gold Ltd. (TSX: KL) announced their second quarter production figures. Results...

Wednesday, July 21, 2021, 11:20:00 AM

Canopy Growth Collects $53 Million From Sale Of Hershey Drive Facility

Canopy Growth (TSX: WEED) has completed the sale of its flagship location in Smith Falls,...

Monday, October 2, 2023, 08:38:11 AM

Cameco: BMO Lifts Price Target To $42 Following Positive Uranium Price Move

On March 30th, BMO Capital Markets raised their rating and 12-month price target on Cameco...

Sunday, April 3, 2022, 11:08:00 AM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM